Medical Advisory Board

Board-certified addiction medicine physician with over 15 years of clinical experience treating substance use disorders. Has authored peer-reviewed research on psychedelic-assisted therapies and serves as a clinical consultant for treatment outcome studies. Provides primary medical oversight for all treatment-related content.

Board-certified psychiatrist specializing in treatment-resistant conditions and trauma recovery. Has extensive experience evaluating psychedelic-assisted protocols for PTSD and depression, with research focused on neuroplasticity-based interventions for complex trauma survivors.

Clinical pharmacologist with dual doctorate in pharmacy and pharmacology. Specializes in alkaloid pharmacokinetics, drug-drug interactions, and metabolic pathways. Reviews all medication interaction content and pharmacological mechanism descriptions for clinical accuracy.

Board-certified cardiologist and Fellow of the American College of Cardiology specializing in drug-induced cardiac arrhythmias and QT prolongation risk. Reviews all cardiac safety content and screening protocol recommendations to ensure alignment with current electrophysiology guidelines.

Neuroscientist specializing in psychedelic pharmacology and neuroplasticity mechanisms. Research focuses on how ibogaine and its metabolite noribogaine affect neural growth factors, serotonin receptors, and addiction-related brain circuits. Reviews all neuroscience and research content.